Cinacalcet Targets the Neurokinin-1 Receptor and Inhibits PKC δ/ERK/P65 Signaling to Alleviate Dextran Sulfate Sodium-Induced Colitis

Conclusion: Cinacalcet inhibits the activation of NF-κB and reduces the production of inflammatory cytokines by suppressing the PKCδ/ERK/P65 signaling pathway via targeting NK1R, suggesting that it can be used to treat inflammatory diseases, particularly colitis.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research